Press Release
Source: Viral Genetics, Inc.

Dr. Louis W. Sullivan, M.D., Joins Scientific and Medical Advisory Board of Viral Genetics, Inc.

Former US Secretary of Health and Human Services Committed to Helping Address AIDS Epidemic in Africa

AZUSA, Calif., June 1, 2005 /PRNewswire-FirstCall/ -- Viral Genetics, Inc. (OTC Bulletin Board: VRAL), a drug development company developing a biological therapy for the treatment of HIV infection, today announced the addition of Louis W. Sullivan, M.D., to its Scientific and Medical Advisory Board.

Dr. Sullivan, who is the host of the public television series, Frontiers of Medicine, served as the U.S. Secretary of Health and Human Services from 1989-1993 during the first Bush presidency. He is the founding dean, director, and current President Emeritus of the Morehouse School of Medicine in Atlanta where he is working to develop a center to focus on the AIDS epidemic in Africa.

“We are pleased to add a physician of Dr. Sullivan’s stature to our board of recognized leaders searching for treatments for HIV/AIDS,” commented Haig Keledjian, Viral Genetics’ President and CEO. “Our Phase III trial of VGV-1 for the treatment of HIV-1 is currently underway in South Africa and his focus on the AIDS epidemic in Africa make this a particularly synergistic fit,”

”Viral Genetics is working to develop a drug that may offer some hope in the struggle to confront HIV/AIDS in Africa and other parts of the world where the problem is reaching pandemic proportions,” said Dr. Sullivan. “I am committed to working with the company to share my insights and assist in whatever way I can to further these scientific advances.”

Dr. Sullivan is Co-Chairman of the President’s Commission on HIV and AIDS, and sits on the boards of Bristol-Myers Squibb, the 3M Corporation, Georgia Pacific, CIGNA Corporation, BioSante Pharmaceuticals, United Therapeutics Corporation, Henry Schein, and Inhibitex. He also serves on numerous non-profit and charitable foundations across the country.

Born in Atlanta, Dr. Sullivan received a Bachelor of Science degree, magna cum laude, from Morehouse College and earned his medical degree, cum laude, from Boston University. His internship and medical residency were at the New York Hospital-Cornell Medical Center. He is certified in internal medicine and hematology. Dr. Sullivan has served on the faculties of Harvard University, Seton Hall College of Medicine and Boston University School of Medicine.

About Viral Genetics, Inc.
Viral Genetics, Inc. is a drug discovery and development company based in southern California developing treatments for infectious disease, autoimmune disease and immunological deficiency through its patented Thymus Nuclear Protein technology. For more information, visit www.viralgenetics.com.

This news release contains forward-looking statements that involve risks and uncertainties associated with clinical development, regulatory approvals, and other risks described by Viral Genetics, Inc. from time to time in its periodic reports with the Securities and Exchange Commission. VGV-1 and TNP are not approved by the US Food and Drug Administration or by any comparable regulatory agencies elsewhere in the world. While Viral Genetics, Inc. believes that the forward-looking statements and underlying assumptions contained therein are reasonable, any of the assumptions could be inaccurate, including the ability of Viral Genetics, Inc., to obtain adequate financing sufficient to meet its business objectives on reasonable terms and conditions, and therefore, there can be no assurance that the forward-looking statements included in this release will prove to be accurate. In light of the significant uncertainties inherent in the forward-looking statements included herein, the forward-looking statements should not be regarded as a representation by the Company or any other person that the objectives and plans of the Company will be achieved.

Contact:
For Information:
Kathy Lane
Investor Relations
760.771.2236

Source: Viral Genetics, Inc.

Click here to return to our Press Release selection page.

Press Releases

Media Kits

Media Inquiries

News Subscription Service